School of Medicine joins exclusive pediatric neuro-oncology consortium

Read More

From the WUSTL Newsroom…

In less than a year, Madeline Thompson, 8, learned she had a brain tumor, underwent two surgeries and endured extensive chemotherapy.

“There was a point when it didn’t look good for Maddie, and I had to prepare for the worst,” said her mother, Katra Thompson. “But today she is as close to cancer-free as possible.”

Thompson, of Hannibal, Mo., credited the Pediatric Neuro-Oncology staff at Washington University School of Medicine in St. Louis and St. Louis Children’s Hospital.

“Everyone is so devoted to making Maddie better,” said Thompson, who shared popcorn with her daughter on a recent afternoon while Maddie received treatment. “I am so happy Maddie can go here because the doctors and staff are the best in the industry.”

Others agree. The Pediatric Neuro-Oncology program recently joined a prestigious network of the nation’s top childhood cancer centers. That development widens treatment options for children whose brain tumors don’t respond to standard care.

The network, the Pacific Pediatric Neuro-Oncology Consortium, provides physicians with access to the latest technologies as well as clinical trials at its 15 medical centers, thereby expanding overall treatment options, and, ideally, patient success rates, said the program’s co-directors: the School of Medicine’s Joshua B. Rubin, MD, PhD, professor of pediatrics and of neuroscience; and David D. Limbrick, MD, PhD, an associate professor of neurological surgery and of pediatrics.

For the complete article, click here.

Posted on March 24, 2016
Posted in: HPAN, Neurodegeneration, Neurogenetics, News Authors: ,